On January 15, 2021, the Patented Medicines Prices Review Board
("PMPRB") initiated a consultation on
two proposed amendments to the new PMPRB Guidelines
("Guidelines"): (1) the definition of
Gap medicines; and (2) the compliance timeline for Grandfathered
and Gap medicines.
According to the PMPRB, the two amendments were required due to
the change in the coming-into-force date of the Regulations
Amending the Patented Medicines Regulations
("Regulations"), which was pushed from
January 1, 2021 to July 1, 2021.
And so, on March 17th, the PMPRB rendered its
decision.
Definition of Gap Medicines.
Under the Guidelines, Gap medicines were defined as those which
were assigned a DIN was on or after August 21, 2019 (the date the
Regulations were adopted) and were first sold in Canada prior to
January 1, 2021. Following the consultation, the PMPRB has extended
the date of first sale to July 1, 2021. This means the Gap medicine
provisions in the Guidelines will now